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Prebiopsy MRI: Through the Looking Glass
A diagnostic test can be defined as any test used to determine
the presence, nature, or severity of a particular condition. In
our technology-driven era, we may like to believe that the
best diagnostic test is the one that provides the most details
with the highest accuracy for the condition being investigat-
ed. However, the most sophisticated and precise test is
useless if its results do not change patient management or
improve relevant outcomes. In other words, it is the
physician’s responsibility to define the right level of detail
of the diagnostic test, beyond which further magnification
does not result in additional clinical consequences. This
dilemma applies to many diagnostic tests used in urological
practice (Does ultrasensitive prostate-specific antigen [PSA]
detect relevant biochemical recurrence? Does novel imaging
detect relevant metastasis?). It also applies to developments
in prostate biopsy indication and procedure. Is the develop-
ment aimed at providing the most accurate representation of
the tissue of the whole gland, and particularly of the different
prostate cancer (PCa) foci that may be present? Or is it (only)
aimed at retrieving the necessary information to adequately
risk stratify a patient for clinical decision-making?
In their Platinum Opinion paper, Vickers et al [1] argue
that routinely performing magnetic resonance imaging
(MRI) before a first set of prostate biopsies is not justified,
which is in contradiction to clinical practice guidelines that
now recommend using MRI in this setting on the basis of
level 1 evidence [2]. Two main arguments against the use of
MRI are provided: systematic biopsy (SB) provides sufficient
detection of clinically significant PCa (csPCa), and the use of
MRI lesion–targeted biopsy (TB) induces a grade migration
that may lead to overtreatment. Does our new looking glass
mostly cause tunnel vision?DOI of original article: https://doi.org/10.1016/j.eururo.2020.04.016.
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tion of biopsy-naïve patients [3–5], it seems difficult to
believe that it provides adequate detection of csPCa. In the
Danish cohort cited by Vickers et al, among patients with
negative SB, the true 20-yr PCa-specific mortality at 20 yr
was 5.2% [6]. The rate of 0.7% cited must be interpreted with
caution, as these data only relate to a subgroup of patients
with PSA < 10 ng/mL, and PSA measurements at diagnosis
were available for only 22% of the cohort. In the Göteborg
screening trial, for men with negative SB in the first
screening round and PSA levels of 3–10 ng/ml the 20-yr
cumulative PCa mortality was 0.6%; for those with PSA
> 10 ng/mL the PCa mortality was 21.4% [7]. Metastasis and
PCa mortality do occur after negative SB and an imperfect
diagnostic strategy may be a cause.
Second, there is no doubt that use of MRI and TB
increases the detection of grade group 2 cancers [3–
5,8,9]. We agree with Vickers et al that the use of a more
sensitive test may induce stage/grade migration due to the
Will Rogers effect (Fig. 1). A grade group 2 cancer only
detected at TB is on average a different tumour to a grade
group 2 lesion already found at SB; it is likely to be on
average smaller (and if risk is a combination of grade and
tumour size, also of lower risk). Notably, stage/grade
migration constantly occurred during the last 50 yr as the
biopsy indication and technique evolved from digital rectal
examination–guided biopsy to PSA-based transrectal ultra-
sound (TRUS)-guided six-core (sextant) lateralised biopsy,
to TRUS-guided 12-core (or more) biopsy. The 2005 Inter-
national Society of Urological Pathology (ISUP) reclassifica-
tion of the Gleason grading system into grade groups led to
another grade migration.
But a stage/grade shift is not a reason to abandon the MRI
looking glass and stick to blind sampling of the gland,
because it does not rule out the chance that additional csPCa
will also be detected after MRI and TB. Not all grade group
2 cancers detected by MRI/TB and missed by SB are
insignificant cancers. Improved prostate mapping using
MRI and TB, by providing a more sensitive test for ISUP score
(one of the most robust predictors of clinical outcomes), isrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine
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Fig. 1 – Schematic representation of different scenarios for a new
diagnostic test versus a reference test. The low-risk group is considered
for expectant management, while high-risk cases are considered for
treatment. Reference test: established risk groups represent the
significance of the disease. Insignificant cases are overdetected and
significant cases are underdetected. Scenario A for the new test: stage
shift only for the risk groups with no difference in the significance of
the disease and a risk of overtreatment. Scenario B for the new test: no
detection of insignificant disease and detection of only significant
disease, which represents a perfect test. Scenario C for the new test:
combined effect, with a lower rate of testing, a reduction in
overdetection of insignificant disease, and improved detection of
significant disease.
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refinement of current risk groups using clinical outcomes of
MRI-based diagnosed PCa [10].
While waiting for data for patients with TB-diagnosed
PCa to mature, we believe that rather than rejecting MRI for
biopsy-naïve patients, the urological community should
adopt a pragmatic approach by mitigating the potential
consequences of stage/grade migration. Thus, recognising
that improved targeting could artificially inflate the ISUP
grade of the tumours by focusing the sampling at areas of
high-grade cancer, a recent ISUP consensus conference has
already suggested the use of an aggregated ISUP grade
summarising the results of all the targeted biopsy cores
rather than the worst core from the same MRI-identified
lesion [11]. In addition, results from TB should also not be
interpreted as stand-alone but in the light of the clinical
context, MRI parameters such as the apparent diffusion
coefficient and tumour size, PSA density, and SB results. As a
result, a greater proportion of grade group 2 cancers may
become eligible for active surveillance [12].
An essential point not addressed by Vickers et al is that
concordant studies suggest that a biopsy indication strategy
combining high-quality MRI and clinical and biochemical
data (such as PSA density) improves the selection forPlease cite this article in press as: van den Bergh RCN, et al. Re: And
Use of Magnetic Resonance Imaging for Early Detection of Prostate
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decrease the number of unnecessary biopsies and resulting
postbiopsy complications. Although SB is currently still
recommended in addition to TB, the strategy has the
potential to also reduce diagnosis of grade group 1 cancers
[2].
In conclusion, there is clear evidence that MRI and TB
improve the detection of grade group 2 cancer over SB.
This higher rate should be interpreted with care. Some
detected cancers may correspond to small cancers as a
result of stage/grade migration, while others may be
aggressive tumours that would otherwise have been
missed. The urological community should adapt risk
classification in order to correctly separate the wheat from
the chaff in the MRI era. Importantly, growing evidence
suggests that MRI, in combination with clinical data, could
also help in selecting patients with very low-risk cancer
who do not need to undergo biopsy at all. The advantages of
using prebiopsy MRI clearly outweigh the suggested harms.
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